Stay updated with breaking news from Power Grp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Judge Engelmayer in the Southern District of New York recently granted a motion to dismiss the complaint because the patent-in-suit is directed to patent-ineligible subject matter under...
CareDx is the exclusive licensee of U.S. Patents 8,703,652, 9,845,497, and 10,329,607 entitled "Non-Invasive Diagnosis of Graft Rejection in Organ Transplant Patients" owned by Stanford.
In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.
The law of unintended consequences provides that actions “always have effects that are unanticipated or unintended.” This folk wisdom holds true when it comes to the Patent Eligibility...
296-1. Federal Circuit Finds Pre-Invention Ideas Not Covered Under Employment IP Assignment Agreement - The United States Court of Appeals for the Federal Circuit...